IPCALAB — Ipca Laboratories Balance Sheet
0.000.00%
- IN₹367.92bn
- IN₹384.90bn
- IN₹89.40bn
- 97
- 11
- 70
- 65
Annual balance sheet for Ipca Laboratories, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
C2021 March 31st | R2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 7,688 | 13,701 | 21,801 | 8,454 | 11,051 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 10,312 | 11,531 | 11,962 | 19,271 | 21,927 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 34,370 | 44,572 | 51,893 | 55,389 | 59,670 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 21,465 | 25,026 | 26,946 | 46,632 | 46,853 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 60,684 | 76,235 | 86,264 | 111,013 | 117,606 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 11,605 | 14,659 | 18,058 | 23,556 | 23,862 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 13,667 | 21,587 | 27,844 | 47,691 | 48,121 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 47,017 | 54,648 | 58,420 | 63,322 | 69,485 |
Total Liabilities & Shareholders' Equity | 60,684 | 76,235 | 86,264 | 111,013 | 117,606 |
Total Common Shares Outstanding |